These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 10102489)

  • 21. Hemophilia treatment. Side effects during immune tolerance induction.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Haematologica; 2000 Oct; 85(10 Suppl):75-7. PubMed ID: 11187878
    [No Abstract]   [Full Text] [Related]  

  • 22. Inhibitors in young boys with haemophilia.
    Lusher JM
    Baillieres Best Pract Res Clin Haematol; 2000 Sep; 13(3):457-68. PubMed ID: 11030045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemophilia factor VIII therapy. Immunological tolerance. A clinical perspective.
    White GC; Greenwood R; Escobar M; Frelinger JA
    Haematologica; 2000 Oct; 85(10 Suppl):113-6. PubMed ID: 11187862
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reactivation of chronic hepatitis C virus infection by immunoadsorption in factor VIII inhibitor haemophilia.
    Rommel F; Toepfer M; Eberle J; Schiffl H; Spannagl M; Schramm W
    Thromb Haemost; 2000 Oct; 84(4):733-4. PubMed ID: 11057884
    [No Abstract]   [Full Text] [Related]  

  • 26. Circulating antibodies in factor VIII deficiency hemophilia: report of case.
    Cudzinowski L
    ASDC J Dent Child; 1979; 46(1):54-6. PubMed ID: 283081
    [No Abstract]   [Full Text] [Related]  

  • 27. Purity of factor VIII product and incidence of inhibitors in previously untreated patients with haemophilia A.
    Mauser-Bunschoten EP; van der Bom JG; Bongers M; Twijnstra M; Roosendaal G; Fischer K; van den Berg HM
    Haemophilia; 2001 Jul; 7(4):364-8. PubMed ID: 11442640
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The development and characterisation of antibodies to human factor VIII in haemophilic dogs.
    Littlewood JD; Barrowcliffe TW
    Thromb Haemost; 1987 Jun; 57(3):314-21. PubMed ID: 3116702
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Porcine factor VIII therapy in patients with congenital hemophilia and inhibitors: efficacy, patient selection, and side effects.
    Hay CR; Lozier JN; Lee CA; Lafan M; Tradati H; Santagostino E; Ciavarella N; Schiavoni M; Fukui H; Yoshioka A
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):20-5. PubMed ID: 7939768
    [No Abstract]   [Full Text] [Related]  

  • 30. [Inhibitors (antibodies) directed against factor VIII in hemophilia A (author's transl)].
    Beck EA
    Ther Umsch; 1979 Apr; 36(4):326-9. PubMed ID: 377556
    [No Abstract]   [Full Text] [Related]  

  • 31. Risk of inhibitors in previously untreated patients with hemophilia: a meta-analysis of literature studies.
    Di Minno MN; Marchesini E; Valdrè L
    Blood; 2015 Jun; 125(24):3819-21. PubMed ID: 26069336
    [No Abstract]   [Full Text] [Related]  

  • 32. Factor VIII brand and immunogenicity.
    Ragni MV
    Blood; 2014 Nov; 124(23):3337-8. PubMed ID: 25431473
    [No Abstract]   [Full Text] [Related]  

  • 33. Suggestions for the management of factor VIII inhibitors.
    Rubinger M; Rivard GE; Teitel J; Walker H;
    Haemophilia; 2000 Jul; 6 Suppl 1():52-9. PubMed ID: 10982269
    [No Abstract]   [Full Text] [Related]  

  • 34. Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX.
    Lollar P
    J Thromb Haemost; 2004 Jul; 2(7):1082-95. PubMed ID: 15219191
    [No Abstract]   [Full Text] [Related]  

  • 35. Statistical modelling issues in the RODIN study.
    Moorehead PC
    Haemophilia; 2014 Jul; 20(4):e351-2. PubMed ID: 24827780
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
    Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
    Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Changes in CD4 count relative to product usage: findings from the transfusion safety study.
    Hilgartner MW
    Semin Hematol; 1993 Oct; 30(4 Suppl 5):7-9. PubMed ID: 7903481
    [No Abstract]   [Full Text] [Related]  

  • 38. The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability.
    Verbruggen B; Novakova I; Wessels H; Boezeman J; van den Berg M; Mauser-Bunschoten E
    Thromb Haemost; 1995 Feb; 73(2):247-51. PubMed ID: 7792738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of alloantigens in blood products on immunity.
    Ludlam CA
    Semin Hematol; 1988 Apr; 25(2 Suppl 1):3-7. PubMed ID: 3133775
    [No Abstract]   [Full Text] [Related]  

  • 40. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Baglin T; Beacham E
    Thromb Haemost; 1998 Dec; 80(6):1036-7. PubMed ID: 9869186
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.